November 10, 2023 News by Marisa Wexler, MS ATA188 fails to outperform placebo in EMBOLD clinical trial ATA188, an experimental cell therapy targeting the Epstein-Barr virus, failed to outperform a placebo at easing disability levels in people with nonactive progressive forms of multiple sclerosis (MS), according to data from the Phase 2 portion of the EMBOLD clinical trial. The medication also showed no signs of…
August 21, 2023 News by Margarida Maia, PhD EMBOLD data covering over 90 MS patients now due in November Atara Biotherapeutics now is planning to announce in November the one-year data from its EMBOLD Phase 1/2 study, which is testing the company’s experimental treatment ATA188 for progressive forms of multiple sclerosis (MS). The results, originally expected in October, will cover the trial’s primary endpoint of…
October 31, 2022 News by Lindsey Shapiro, PhD #ECTRIMS2022 ā ATA188 Still Easing Disability in Progressive MS Patients The investigational immunotherapy ATA188 continues to ease disability and prevent brain tissue shrinkage in people with progressive forms of multiple sclerosis, according to the data, now reachingĀ up to four years, on patients in an ongoing clinical trial. People who achieved confirmed disability improvement also showedĀ potentialĀ signs of remyelination, or…
July 14, 2022 News by Marisa Wexler, MS EMBOLD Study of ATA188 in Progressive MS Is Given Go-ahead An independent committee of experts has recommended that the Phase 2 portion of the EMBOLD clinical trial continue as planned without a sample size adjustment, following an analysis of safety and effectiveness data. The trial is testing Atara Biotherapeutics‘ experimental medication ATA188 in progressive forms of multiple…
April 19, 2022 News by Marta Figueiredo, PhD Atara Planning Phase 3 Trials of ATA188 in Non-active SPMS, PPMS Atara BiotherapeuticsĀ plans to launch two Phase 3 clinical trials of its investigational immunotherapy ATA188 in people with non-active, progressive forms of multiple sclerosisĀ (MS). Whether efforts for these trials will go forward, however, depends on positive results from an interim analysis of the Phase 2 portion of the…
February 1, 2022 News by Marisa Wexler, MS Atara, Fujifilm Enter Deal to Produce Cell Therapies Atara Biotherapeutics has reached an agreement withĀ Fujifilm Diosynth Biotechnologies for the production of its cell therapy pipeline, including ATA188, an experimental therapy being investigated for the treatment of progressive multiple sclerosis (MS). Under the agreement, Fujifilm will acquire Ataraās T-Cell Operations and Manufacturing (ATOM) facility in Thousand…
January 25, 2022 News by Marisa Wexler, MS Study Explains How Epstein-Barr Virus Infection Could Cause MS Similarities between an Epstein-Barr virus (EBV) protein and a brainĀ protein called GlialCAM may explain why EBV infection increases the risk of multiple sclerosis (MS), results from a new study show. Due to the structural resemblance of the two proteins, B-cells ā a type of immune cell that is critical…
September 30, 2021 News by Steve Bryson, PhD #ECTRIMS2021 – ATA188 Benefits in SPMS, PPMS Hint at Remyelination An investigational immunotherapy, ATA188Ā showed it could reverse disability and improve exercise capacity in people with progressive forms of multiple sclerosis (MS), Atara Biotherapeutics, its developer, reported in an update on a Phase 1 trial and its long-term extension study. EMBOLD trial findings based on MRI brain imaging…